安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- ENJAYMO® (sutimlimab-jome) | Cold Agglutinin Disease Treatment
ENJAYMO is the first and only FDA-approved treatment for people with cold agglutinin disease (CAD) to help decrease the need for red blood cell transfusion Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction and will treat your symptoms if needed Tell your healthcare provider right
- ENJAYMO® (sutimlimab-jome) | What is ENJAYMO?
ENJAYMO is a chemotherapy-free treatment proven to help stop the destruction of red blood cells (hemolysis) in cold agglutinin disease (CAD) Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction and will treat your symptoms if needed Tell your healthcare provider right away if you
- ENJAYMO® (sutimlimab-jome) | ENJAYMO Dosing
The ENJAYMO dosing schedule is designed to provide a continuous level of medicine ENJAYMO is given as an intravenous (IV) infusion weekly for the first 2 weeks, and then every 2 weeks thereafter Your dose of ENJAYMO (either 6 5 g or 7 5 g) is based on your body weight, which your doctor will determine for you
- HIGHLIGHTS OF PRESCRIBING INFORMATION - enjaymo. com
Administer ENJAYMO infusion solution only through a 0 2 micron in-line filter with a polyethersulfone (PES) membrane • The infusion catheter and tubing should be primed with the dosing solution imme-diately before infusion and flushed immediately following completion of the infusion
- ENJAYMO® (sutimlimab-jome) | Resources
Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction and will treat your symptoms if needed
- ENJAYMO® (sutimlimab-jome) | What is Cold Agglutinin Disease?
Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction and will treat your symptoms if needed Tell your healthcare provider right
- ENJAYMO® (sutimlimab-jome) | How ENJAYMO Can Help Treat CAD
Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction and will treat your symptoms if needed
- ENJAYMO® (sutimlimab-jome) | FAQ
ENJAYMO is first given every week for 2 weeks, then you'll get an infusion every 2 weeks after that An infusion can take 1 to 2 hours, plus an additional 2 hours to monitor for infusion-related and or allergic reactions — then monitored for infusion reactions for an hour
|
|
|